Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Plasma cell 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Sarcoma 2Oligodendroglioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Dendritic Cell Sarcoma, Interdigitating 1Chordoma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cyclophosphamide 58Filgrastim 37Radiotherapy 31Busulfan 28fludarabine phosphate 26Antilymphocyte Serum 25Cyclosporine 24Peripheral Blood Stem Cell Transplantation 23Etoposide 22Methotrexate 20Melphalan 18Mycophenolic Acid 17Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Vincristine 13Cytarabine 13Tacrolimus 12Rituximab 11Whole-Body Irradiation 9Thiotepa 9Prednisone 9Doxorubicin 8Leucovorin 7sargramostim 6aldesleukin 6Granulocyte Colony-Stimulating Factor 6Psychiatric Rehabilitation 5Daunorubicin 5pembrolizumab 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Panobinostat × Sarcoma × Clear all
NCT01282476 2017-05-09

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡